SAN MATEO, Calif.--(BUSINESS WIRE)--EndoGastric Solutions (EGS) today announces six-month results from world’s first-ever randomized, sham- and placebo-controlled prospective clinical study of the TIF® procedure; the data demonstrates that the TIF procedure is more effective than twice daily proton pump inhibitor (PPI) drug at eliminating troublesome regurgitation in patients with chronic gastroesophageal reflux disease (GERD).
The data from the RESPECT (Randomized EsophyX® vs. Sham/Placebo Controlled Trial) will be presented at the ACG 2014 Annual Scientific Meeting and Postgraduate Course in Philadelphia, PA during “Plenary Session 1: Esophagus” starting at 2:15 PM EST Tuesday, October 21, 2014 by Peter Kahrilas, MD, Professor of Medicine-Gastroenterology, Northwestern University and co-principal investigator.
Help employers find you! Check out all the jobs and post your resume.
